  Fibrosis is a common lesion in different pathologic diseases and is defined
by the excessive accumulation of collagen. Different approaches have been used
to treat different conditions characterized by fibrosis. FDA and EMA approved
collagenase to treat palmar fibromatosis, Dupuyten disease. EMA approved
additionally its use in severe Peyronie disease, but it has been used off label
in other conditions.1, 2. Approved treatment includes up to 3, in palmar
fibromatosis or up to 8, in penile fibromatosis, injections followed by finger
extension or penile modelling procedures, typically causing severe pain.
Frequently single injections are enough to treat palmar fibromatosis. 3, The
need to inject repeatedly doses of this enzyme can be originated by by the
labile nature of collagenase which exhibits a complete activity loss after
short periods of time. Herein, a novel strategy to manage this enzyme based on
the synthesis of polymeric nanocapsules which contains collagenase housed
within their matrix is presented. These nanocapsules have been engineered for
achieving a gradual release of the encapsulated enzyme for longer times which
can be up to ten days. The efficacy of these nanocapsules have been tested in
murine model of local dermal fibrosis yielding higher fibrosis reduction in
comparison with the injection of free enzyme which represent a significant
improvement over conventional therapy.
